Salom-Garrigues, Clara
Aragonès, Enric
Giralt, Montse
Campabadal Prats, Cecília
Bejarano-Romero, Ferran
Canadell, Laura
Funding for this research was provided by:
Jordi Gol Primary Care Research Institute (IDIAPJGol), Barcelona, Spain (7Z21/011)
Article History
Received: 25 June 2023
Accepted: 30 January 2024
First Online: 19 February 2024
Declarations
:
: This study has been designed according to the Good Practice Guide in Health Sciences Research of the Catalan Health Institute, the Declaration of Helsinki principles of the World Medical Association modified in 2013, and applicable regulations. The physician in charge will inform the patients, their caregivers and/or their legal guardians about the aims and general aspects of the study, any drawbacks of the eventual modification of the treatment plan and how to deal with. Since the pharmaceutical intervention is considered of minimal risk, with an anticipated probability and magnitude of harm or discomfort not greater than those encountered in ordinary clinical practice, the responsible physician will obtain verbal consent from all patients for participation. The protocol, including verbal consent procedure, has been approved by the Clinical Research Ethics Committee (CEIC) of the IDIAPJGol (Barcelona, 20/02/2020; code 19/141-P).
: Not applicable.
: The authors declare no competing interests.